Mouse anti Human Cytochrome P450 2A6

Nordic MuBio
Product Code: EXA-X2045M
Product Group: Primary Antibodies
Supplier: Nordic MuBio
CodeSizePrice
EXA-X2045M200 ug£316.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: F16 P2 D8
Regulatory Status: RUO
Target Species: Human
Applications:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunohistochemistry (IHC)
  • Western Blot (WB)
Shipping:
Ship at ambient temperature freeze upon arrival
Storage:
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Further Information

Applications Description:
Antibody can be used for Western blotting (1-2 ?g/ml), immunofluorescence and immunohistochemistry (formalin-fixed, paraffin-embedded tissues). ELISA titer to be determined by end-user. Optimal concentration should be evaluated by serial dilutions.
Background:
The cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP2A6 is a liver enzyme that metabolizes a number of drugs and a variety of procarcinogens, though it is primarily responsible for the metabolism of nicotine, the major addictive agent in tobacco. CYP2A6 inactivates nicotine to cotinine, and then cotinine to 3-hydroxycotinine. Differences in CYP2A6 genotypes are related to nicotine dependence, and may influence smoking habits and withdrawal symptoms in individuals that are quitting smoking. This suggests that an individualized smoking cessation program may be designed based on CYP2A6 genotypes.
Caution:
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
Concentration:
See vial for concentration
Field of Interest:
Cell Cycle
Formulation:
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Functional Analysis:
Western Blotting
Immunogen:
Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with Synthetic peptide conjugated to ovalbumin derived from the C-terminus of CYP2A6 and mouse myeloma Ag8563 cells. Antigen identical in CYP2A6, 2A7 and 2A13.
Positive Control:
Normal human liver tissue.
Product:
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Product Form:
Unconjugated
Product Stability:
Products are stable for one year from purchase when stored properly
Purification Method:
Protein A/G Chromatography
Source:
Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with Synthetic peptide conjugated to ovalbumin derived from the C-terminus of CYP2A6 and mouse myeloma Ag8563 cells. Antigen identical in CYP2A6, 2A7 and 2A13.
Synonyms:
CYP2A6; CYP450 2A6 (EC 1.14.14.1), CYPIIA6, Coumarin 7-hydroxylase
UniProt:
P05177

References

1. Kumarakulasingham M, et al. (2005). Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. May 15;11(10):3758-65

2. Swan, G.E. (2005). Nicotine metabolism: the impact of CYP2A6 on estimate of additive genetic influence. Pharmacogenet. Genomics 15(2);115-125

3. Higashi, E., et al. (2007). Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos. 35(4); 508-514

4. Audrain-McGovern, J., et al. (2007). The role of CYP2A6 in the emergence of nicotine dependence in adolescents. 119(1);264-274